Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.
Sensei Biotherapeutics, a US-based oncology treatment developer backed by medical research group Cambrian Biopharma, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 1999, Sensei is developing immunotherapies to treat cancer and will put part of the IPO proceeds into an ongoing phase 1/2 clinical trial for its lead drug candidate, SNS-301, for squamous cell carcinoma of the head and neck.
Additional proceeds will fund the preclinical and clinical development of two other…
